糖脉康颗粒联合卡托普利治疗糖尿病肾病的 临床随机对照试验

目的:观察糖脉康颗粒联合卡托普利治疗糖尿病肾病(DN)的临床疗效。方法:160例患者随机分为观察组和对照组,对照组接受卡托普利治疗,25 mg/次,3次/d;观察组接受糖脉康颗粒治疗,5 g/次,3次/日,同时服用卡托普利25 mg/次,3次/d。治疗4周后,观察患者SUN,SCr,24 h尿蛋白的变化。结果:两组患者BUN,SCr,24 h尿蛋白定量在治疗前无显著性差异。治疗4周后,观察组与同组治疗前相比,疗效有显著性差异(P<0.05);对照组与同组治疗前相比,24 h尿蛋白定量有显著性差异外(P<0.05),BUN,SCr虽有所改善,但无统计学意义;治疗后两组相比,效果有显著性差异(P<0.05)。结论:糖脉康颗粒联合卡托普利治疗DN效果优于单纯应用卡托普利。

Randomized Controlled Trials of Tangmaikang Particles Combined with Captopril on Diabetic Nephropathy

Objective: To observe the clinical efficacy of Tangmaikang particles combined with captopril on diabetic nephropathy (DN). Method: 160 patients were randomly divided into two groups which were the observation group and the control group. The control group received captopril treatment, 25 mg/time, three times/d. And the observation group was received Tangmaikang particles 5 g, tid. combined with captopril treatment, 25 mg, tid. BUN, SCr and 24 h urinary protein were observed after 4 weeks treatment. Result: Two groups of patients with BUN, SCr, 24 h urinary protein in pre-treatment was no significant difference. After treatment 4 weeks, the observation group compared with the same group before treatment, efficacy was significant difference (P<0.05); the control group compared with the same group before treatment, 24 h urinary protein was significant difference in external (P<0.05) , BUN, SCr, while improving, but not statistically significant; compared the two groups after treatment, the effect was significant difference (P<0.05). Conclusion: Tangmaikang particles combined with captopril on treatment of DN was better than captopril alone.